CO6960546A2 - Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida - Google Patents

Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida

Info

Publication number
CO6960546A2
CO6960546A2 CO14103891A CO14103891A CO6960546A2 CO 6960546 A2 CO6960546 A2 CO 6960546A2 CO 14103891 A CO14103891 A CO 14103891A CO 14103891 A CO14103891 A CO 14103891A CO 6960546 A2 CO6960546 A2 CO 6960546A2
Authority
CO
Colombia
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
trifluoro
Prior art date
Application number
CO14103891A
Other languages
English (en)
Inventor
Upkar Bhardwaj
Magesh Sadashiv Bordawekar
Anne Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6960546A2 publication Critical patent/CO6960546A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO14103891A 2011-11-14 2014-05-14 Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida CO6960546A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
CO6960546A2 true CO6960546A2 (es) 2014-05-30

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14103891A CO6960546A2 (es) 2011-11-14 2014-05-14 Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida

Country Status (22)

Country Link
EP (1) EP2779995A1 (es)
JP (1) JP6275645B2 (es)
KR (1) KR20140093230A (es)
CN (1) CN103930094A (es)
AR (1) AR088844A1 (es)
BR (1) BR112014011518A2 (es)
CA (1) CA2855503A1 (es)
CL (1) CL2014001247A1 (es)
CO (1) CO6960546A2 (es)
EA (1) EA201490960A1 (es)
GT (1) GT201400094A (es)
HK (1) HK1197025A1 (es)
IL (1) IL232480A0 (es)
IN (1) IN2014DN03416A (es)
MA (1) MA35636B1 (es)
MX (1) MX2014005874A (es)
PE (1) PE20141337A1 (es)
SG (2) SG11201401476TA (es)
TN (1) TN2014000177A1 (es)
TW (1) TWI574690B (es)
WO (1) WO2013074432A1 (es)
ZA (1) ZA201402756B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (es) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
EA201490960A1 (ru) 2014-08-29
HK1197025A1 (en) 2015-01-02
ZA201402756B (en) 2015-04-29
AU2012339829A1 (en) 2014-05-29
CA2855503A1 (en) 2013-05-23
JP2014533283A (ja) 2014-12-11
EP2779995A1 (en) 2014-09-24
CN103930094A (zh) 2014-07-16
AR088844A1 (es) 2014-07-10
WO2013074432A1 (en) 2013-05-23
IL232480A0 (en) 2014-06-30
TW201325594A (zh) 2013-07-01
SG10201707768RA (en) 2017-10-30
IN2014DN03416A (es) 2015-06-26
PE20141337A1 (es) 2014-10-16
SG11201401476TA (en) 2014-10-30
NZ623844A (en) 2016-09-30
GT201400094A (es) 2017-09-28
KR20140093230A (ko) 2014-07-25
MA35636B1 (fr) 2014-11-01
TWI574690B (zh) 2017-03-21
BR112014011518A2 (pt) 2017-05-16
AU2012339829B2 (en) 2016-05-12
JP6275645B2 (ja) 2018-02-07
CL2014001247A1 (es) 2014-10-17
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
CO6801777A2 (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
CY2020017I2 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
IL269977B (en) Compounds 2-(1-isopropyl-pyrazol-5-yl)-3-(hydroxy/chloro)methyl pyridine
HK1217487A1 (zh) 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物
IL239025B (en) fxr agonist - for the treatment of lung diseases
IL242279A (en) Converted compounds of 3-chloro-n- [3 - (pyrimidine-2-ylamino) phenyl] propanamide and their salts
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
DK3409278T3 (da) Heterocykliske proteinkinaseinhibitorer
BR112012017375A2 (pt) artigo descartável do vestuário
PL2421832T3 (pl) N-alkoksyamidy 6-(podstawionych fenylo)-4-aminopikolinianów i 2-(podstawionych fenylo)-6-amino-4-pirymidynokarboksylanów oraz ich zastosowanie jako selektywnych herbicydów dla roślin uprawnych
PL3290414T3 (pl) Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
EP2694060A4 (en) SUBSTITUTED 3- (1H-BENZO [D] IMIDAZOL-2-YL) -1H-INDAZOLE ANALOGUES AS INHIBITORS OF PDK1 KINASE
DK2878598T3 (da) Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
IL234742A0 (en) Salts of 5-[(2,21)]4]-2})-2-(r-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinoline-2(1h)- potency
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof
CO6960546A2 (es) Formulación de liberación inmediata de 4-metil-3[[4-(3-piridinil)-2pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
BR112013008638A2 (pt) inibidores de oxadiazol de produção de leucotrieno
SI2608789T1 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
SG11201604517WA (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
PT2943488T (pt) Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
SI2989095T1 (sl) Tartratna sol 5-kloro-tiopen-2-karboksilne kisline((s)-2-(metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino)-3- (4-metil piperazin-1 il)-3-okso-propril)amida
BR112013025679A2 (pt) inibidores de proteína quinase de novos compostos de indolinona